Table 3

EBV DNA loads in various EBV-associated disease states and immunocompromised individuals.

Group

Patient ID

Sex/Age

Condition

Specimen

(Positive/n Tested)

Target

Detectable EBV DNA Load (copies/ml)

Clinical Notes


1.

A.

M/46y

PTLD

Plasma (5/6)

EBNA-1

Day +32 - 8.0 × 102

MUD HSCT for AML; EBV VCA IgG positive pre-Tx; Plasma collected on Days +32, +39, +46, +60, +75 and +81 for EBV QPCR; Plasma EBV (qualitative) PCR positive on Days +75, +78 and +81; Treatment with Foscarnet and Rituximab after Day +75; Died of pneumonia on Day +88

Day +46 - 1.0 × 103

Day +60 - 8.8 × 103

Day +75 - 1.1 × 106

Day +81 - 2.3 × 105

CSF (2/2)

EBNA-1

Day +75 - 1.3 × 106

CSF collected on Days +75 and +78

Day +78 - 2.7 × 106

B.

M/42y

PTLD

Whole Blood (1/5)

EBNA-1

Day +95 - 2.0 × 107

MUD HSCT for AML; Plasma EBV (qualitative) PCR positive Day +96; Plasma collected on Day +95 for EBV QPCR; Died on Day +99 due to multi-organ failure

C.

F/59y

PTLD

Plasma (3/6)

EBNA-1

Day +45 - 2.2 × 105

MUD HSCT for AML; CMV reactivation on Day +44, Treatment with Foscarnet and ganciclovir on Day +52; Plasma collected Days +38, +40, +45, +52 and +59; Died on Day +66; EBV VCA IgG positive, HHV6 IgG positive and CMV IgG positive pre-Tx

Day +52 - 9.6 × 103

Day +59 - 3.0 × 105

Whole Blood (1/8)

EBNA-1

Day +46 - 6.6 × 104

EDTA collected Days +3, +5, +10, +17, +26, +31, +33, +46

D.

M/48y

PTLD

Plasma (4/6)

EBNA-1

Day +40 - 3.4 × 103

MUD HSCT for AML; EBV VCA IgG positive pre-Tx; Plasma collected Days +28, +33, +40, +47, +54, +61; Plasma EBV (qualitative) PCR negative on Day +62; Died Day +72 of multi-organ failure

Day +47 - 3.6 × 104

Day +54 - 3.4 × 106

Day +61 - 6.3 × 106

Whole Blood (2/2)

EBNA-1

Day +62 - 1.3 × 108

EDTA collected Days +62 and +63.

Day +63 - 1.8 × 107

E.

F/57y

PTLD

Whole Blood (1/5)

EBNA-1

9.5 × 104

No serology results available however clinical notes indicate EBV reactivation; Plasma EBV (qualitative) PCR positive 9-16 days after VL testing done; negative at 1-7 months thereafter.

2.

F.

Unknown

IM

Plasma (1/1)

EBNA-1

3.7 × 104

EBV VCA IgM positive

BHRF-1

1.6 × 104

G.

Unknown

IM

Plasma (0/1)

EBNA-1

0

EBV VCA IgM positive

BHRF-1

0

H.

Unknown

IM

Plasma (1/1)

EBNA-1

7.6 × 103

EBV VCA IgM positive

BHRF-1

1.5 × 103

I.

Unknown

IM

Plasma (1/1)

EBNA-1

2.3 × 103

EBV VCA IgM positive

BHRF-1

8.7 × 104

J.

M/17y

IM

Whole Blood (1/1)

EBNA-1

1.0 × 105

EBV VCA IgM positive

BHRF-1

1.8 × 103

K.

F/19y

IM

Whole Blood (1/1)

EBNA-1

2.2 103

EBV VCA IgM positive

BHRF-1

5.6 × 104

L.

F/53y

IM

Whole Blood (1/1)

EBNA-1

2.0 × 105

EBV VCA IgM positive; acute glandular fever

BHRF-1

1.8 × 104

3.

M.

M/36y

EBVAHS

Whole Blood (1/1)

EBNA-1

7.5 × 104

EBV (qualitative) PCR positive; died of EBVAHS

BHRF-1

1.1 × 105

4.

N.

Unknown

HIV

Plasma (1/1)

EBNA-1

0

HIV plasma VL 324, 000 RNA copies/ml

BHRF-1

1.0 × 103

O.

Unknown

HIV

Plasma (0/1)

EBNA-1,

0

HIV plasma VL 13, 000 RNA copies/ml

BHRF-1

0

P.

Unknown

HIV

Plasma (0/1)

EBNA-1,

0

HIV plasma VL 26, 800 RNA copies/ml

BHRF-1

0

Q.

Unknown

HIV

Plasma (0/1)

EBNA-1,

0

HIV plasma VL 21, 300 RNA copies/ml

BHRF-1

0

R.

Unknown

HIV

Plasma (0/1)

EBNA-1,

0

HIV plasma VL 12, 700 RNA copies/ml

BHRF-1

0

S.

Unknown

HIV

Plasma (0/1)

EBNA-1,

0

HIV plasma VL 1, 040, 000 RNA copies/ml

BHRF-1

0

T.

Unknown

HIV

Plasma (0/1)

EBNA-1,

0

HIV plasma VL 17, 700 RNA copies/ml

BHRF-1

0

U.

Unknown

HIV

Plasma (0/1)

EBNA-1,

0

HIV plasma VL 47, 500 RNA copies/ml

BHRF-1

0

V.

Unknown

HIV

Plasma (1/1)

EBNA-1

5.6 × 103

HIV plasma VL 16, 400 RNA copies/ml

BHRF-1

3.0 × 103

W.

Unknown

HIV

PBMC (1/1)

EBNA-1

< 2.0 × 102

HIV PBMC VL 12, 800 RNA copies/ml

BHRF-1

< 2.0 × 102

X.

Unknown

HIV

PBMC (1/1)

EBNA-1

< 2.0 × 102

HIV PBMC VL 12, 700 RNA copies/ml

BHRF-1

0

Y.

Unknown

HIV

PBMC (0/1)

EBNA-1,

0

HIV PBMC VL 118, 000 RNA copies/ml

BHRF-1


Abbreviations: Y, years; Group 1 (PTLD), post-transplant lymphoproliferative disease; Group 2 (IM), infectious mononucleosis; Group 3 (EBVAHS), Epstein-Barr virus associated-haemophagocytic syndrome; Group 4 (HIV infection), human immunodeficiency virus; EDTA, ethylenediaminetetraacetic acid; CSF, cerebrospinal fluid; PBMC, peripheral blood mononuclear cells; EBNA-1, Epstein-Barr virus nuclear antigen-1; BHRF-1, BamHI fragment H rightward open reading frame-1; ml, millilitres; Bold lettering indicates Day QPCR positive post-transplant; AML, acute myeloid leukaemia; MUD; matched unrelated donor; HSCT, haematopoietic stem cell transplantation; CMV, cytomegalovirus; VCA, viral capsid antigen; Ig, immunoglobulins; EA-D, early antigen-diffuse; EA-R, early antigen-restricted; VL, viral load

Lay et al. Virology Journal 2010 7:252   doi:10.1186/1743-422X-7-252

Open Data